Inixaciclib

Overview

Inixaciclib (NUV-422) is a blood-brain barrier-penetrant inhibitor of CDK2 , CDK4 and CDK6 . Inixaciclib inhibits cancer cell growth. Inixaciclib induces anti-tumor activity in xenograft models of glioblastoma, CDK4 / CDK6 inhibitor-resistant HR + HER2 - metastatic breast cancer , and anti-androgen-resistant prostate cancer . Inixaciclib can be used for the research of relapsed or metastatic castration-resistant prostate cancer .

Application

Products | Products > Disease Areas > Glioma | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Metastatic Breast Cancer | Products > Disease Areas > Castration-Resistant Prostate Cancer | Products > Disease Areas > Metastatic Prostate Cancer | Products > Disease Areas > Glioblastoma | Products > Disease Areas > Cancer | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > CNS Neoplasm | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Neurological Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > CDK

Product Information

• Catalog No.: HY-45661
• CAS No.: 2370913-42-9
• Molecular Formula: C26H30F2N6O
• Molecular Weight: 480.55
• Purity: 99.93%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 1.25 mg/mL (2.60 mM); Clear solution
• Availability: In-stock

Source

Original product source